Open Consultations
-
Weekly Bed Vacancy Data Request - 20 June 2025
Please complete the data survey by close of business today. Please do not use any other to provide your data, as this impacts consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by close of business Monday 23 June 2025. It will...
Closes 23 June 2025
-
MPS Reforms - Implementing 24/7 RN Survey
The purpose of this survey is to provide Multi-Purpose Services with the opportunity to provide feedback regarding the 24/7 RN trial.
Closes 6 July 2025
-
Consultation on the commercial release of a genetically modified (GM) mosquito strain (DIR 207)
The Gene Technology Regulator has received a licence application (DIR 207) from Oxitec Australia Pty Ltd for a commercial release of a genetically modified (GM) mosquito strain to help prevent dengue outbreaks. Comments are now being sought on the consultation version of the Risk Assessment...
Closes 7 July 2025
-
Include COVID-19 Chapter in the Australian Immunisation Handbook
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders to include the COVID-19 chapter in the Australian Immunisation Handbook, with an intention to submit the revised chapter to the National Health and Medical Research Council (NHMRC) for its approval under...
Closes 11 July 2025
-
National Personal Care Worker Qualifications and Training Survey
We want to hear from personal care workers about their qualification and training experiences in the aged care sector.
Closes 17 July 2025
Closed Consultations
-
Weekly Bed Vacancy Data Request - 13 June 2025
Please complete the data survey by close of business today. Please do not use any other to provide your data, as this impacts consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by close of business Monday 16 June 2025. It will...
Closed 16 June 2025
-
Weekly Bed Vacancy Data Request - 6 June 2025
Please complete the data survey by close of business today. Please do not use any other to provide your data, as this impacts consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by end of day, Tuesday 10 June 2025 (due to a public...
Closed 10 June 2025
-
Weekly Bed Vacancy Data Request - 30 May 2025
Please complete the data survey by close of business today. Please do not use any other to provide your data, as this impacts consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by end of day, Monday 2 June 2025. It will assist...
Closed 2 June 2025
-
Weekly Bed Vacancy Data Request - 23 May 2025
Please complete the data survey by close of business today. Please do not use any other to provide your data, as this impacts consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by end of day, Monday 26 May 2025. It will assist...
Closed 26 May 2025
-
Weekly Bed Vacancy Data Request - 19 May 2025
Please complete the data survey by close of business today. Please do not use any other to provide your data, as this impacts consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by end of day, Tuesday 20 May 2025. It will assist...
Closed 20 May 2025
We Asked, You Said, We Did
Here are some of the issues we have consulted on and their outcomes. See all outcomes
We asked
Between 2 April and 13 May 2025, we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for the DIR 215 licence application (field trial of genetically modified canola from Miruku Australia Pty Ltd).
You said
During the 6-week consultation period, we received advice from prescribed Government agencies, the Gene Technology Technical Advisory Committee, and the public.
We heard support for:
- the proposed limits and controls listed in the RARMP
- the uncertainties identified in the RARMP
- the overall conclusions of the RARMP.
Some submissions sought clarification on the potential for increased weediness as a result of the inserted fusion protein, the ability to inspect for related species, and on oversight of the proposed sensory testing.
We did
We analysed the feedback provided during the public consultation process in finalising the RARMP. The issues raised and how they were addressed can be found in Appendices A and B of the final RARMP.
The Gene Technology Regulator issued a licence to Miruku Australia Pty Ltd for their research work with the GM canola on 16 June 2025. More details, including the final version of the RARMP and the licence, are available at DIR 215 | Office of the Gene Technology Regulator.
We appreciate all those who provided input to the consultation – your feedback will help to ensure that any risks posed by gene technology to people and the environment continue to be managed.
We asked
Between 17 March to 28 April we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for DIR-214 licence application (Trial of a genetically modified (GM) vaccine for the prevention of respiratory disease in horses).
You said
During the 6-week consultation period we received email advice from prescribed Government agencies and the Gene Technology Technical Advisory Committee but did not receive any public feedback.
We heard support for:
- the thoroughness of the RARMP
- the proposed limits and controls listed in the RARMP
- the overall conclusions of the RARMP
We did
We analysed the feedback provided during the public consultation process and took into account submitter suggestions to improve clarity on the methods of decontamination and the origin of the genetic material inserted into the GMO in finalising the RARMP (comments addressed in Appendix A).
The Gene Technology Regulator issued a licence to The University of Queensland for their research work with the GM vaccine for horses on 4 June 2025. More details are available at DIR 214 | Office of the Gene Technology Regulator.
We appreciate all those who provided input to the consultation – your feedback will help to ensure the OGTR continues to manage any risks posed by gene technologies to people and the environment.
We asked
Between 6 March and 17 April 2025, we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for the DIR 212 licence application (field trial of genetically modified canola from The University of Adelaide).
You said
During the 6-week consultation period, we received advice from prescribed Government agencies and the Gene Technology Technical Advisory Committee, and received email submissions from the public.
We heard support for:
- the proposed limits and controls listed in the RARMP
- the uncertainties identified in the RARMP
- the overall conclusions of the RARMP.
Some submissions sought clarification on the effect of overexpression of one of the inserted genes, the potential for pollen flow outside the trial, and on requirements for further data about the GMOs.
We did
We analysed the feedback provided during the public consultation process in finalising the RARMP. The issues raised and how they were addressed can be found in Appendices A and B of the final RARMP.
The Gene Technology Regulator issued a licence to The University of Adelaide for their research work with the GM canola on 21 May 2025. More details, including the final version of the RARMP and the licence, are available at DIR 212 | Office of the Gene Technology Regulator.
We appreciate all those who provided input to the consultation – your feedback will help to ensure that any risks posed by gene technology to people and the environment continue to be managed.